title: Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution.
abstract: Forty-five cases of fungaemia due non-albicans Candida spp. (NAC) in a single National Cancer Institution within 10 years were analysed for aetiology, risk factors and outcome. There had been 12 cases of fungaemia that were due to C. krusei, 14 due to C. parapsilosis, 7 due to C. (T.) glabrata, 6 to C. tropicalis, 2 to C. guillermondii, 2 to C. lusitaniae, 1 to C. stellatoidea, and 1 to C. rugosa. Comparison of 45 NAC fungaemia with 75 episodes of C. albicans fungaemia revealed differences only in two risk factors: previous empiric therapy with amphotericin B (16.0 vs 2.2%, P<0.01) appeared more frequently in cases of C. albicans fungaemia, and prior prophylaxis with fluconazole (8.9 vs 0%, P<0.02) was conversely more frequently observed with NAC. The incidence of other risk factors, such as underlying disease, chemotherapy, antibiotic prophylaxis or therapy, treatment with corticosteroids, catheter insertion, mucositis, cytotoxic chemotherapy, and neutropenia, was similar in both groups. There was no difference either in attributable or in overall mortality between NAC and C. albicans fungaemia in our cancer patients.
authors.affiliation: Department of Microbiology, Department of Oncology, National Cancer and St. Elizabeth's Cancer Institutes, Klenova 10, 833 10 Bratislava, Slovak Republic.
authors.forename: V
authors.initials: V
authors.lastname: Krcmery
authors.forename: M
authors.initials: M
authors.lastname: Mrazova
authors.forename: A
authors.initials: A
authors.lastname: Kunova
authors.forename: E
authors.initials: E
authors.lastname: Grey
authors.forename: J
authors.initials: J
authors.lastname: Mardiak
authors.forename: L
authors.initials: L
authors.lastname: Jurga
authors.forename: A
authors.initials: A
authors.lastname: Sabo
authors.forename: J
authors.initials: J
authors.lastname: Sufliarsky
authors.forename: L
authors.initials: L
authors.lastname: Sevcikova
authors.forename: D
authors.initials: D
authors.lastname: Sorkovska
authors.forename: D
authors.initials: D
authors.lastname: West
authors.forename: J
authors.initials: J
authors.lastname: Trupl
authors.forename: J
authors.initials: J
authors.lastname: Novotny
authors.forename: F
authors.initials: F
authors.lastname: Mateicka
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000706:statistics & numerical data; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002175:Candida / Q000145:classification*; D002176:Candida albicans / Q000254:growth & development; D002177:Candidiasis / Q000453:epidemiology*; D002404:Catheterization / Q000295:instrumentation; D016009:Chi-Square Distribution; D003428:Cross Infection / Q000453:epidemiology*; D015725:Fluconazole / Q000627:therapeutic use; D016469:Fungemia / Q000453:epidemiology*; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000453:epidemiology; D009503:Neutropenia / Q000453:epidemiology; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D012307:Risk Factors; D018154:Slovakia / Q000453:epidemiology
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000666:Amphotericin B; D015725:Fluconazole